Bone Therapeutics Appoints Chief Financial Officer

BONE THERAPEUTICS, a bone cell therapy company addressing high unmet medical needs in orthopedics and bone diseases, thas appointed Jean-Luc Vandebroek as chief financial officer (CFO), effective Sept. 1. Vandebroek replaces Wim Goemaere, who is leaving the company to take up a senior position within a not-for-profit organization. Goemaere will continue to support the company as a non-executive director, and will lead a managed succession during the transition period.

Vandebroek is a seasoned finance executive with extensive international finance experience at major public and privately-owned companies. He has built a career spanning 15 years at the Belgian-U.S. retailer Delhaize Group (now Ahold Delhaize). During this period, he held various senior financial positions with increasing responsibility, including roles as corporate director of finance for Europe and the United States, and vice president of finance BeLux. Vandebroek later became group CFO at Fluxys, a listed, pan-European gas infrastructure group, where he was responsible for the financing of large infrastructure investments using diverse forms of funding on capital markets. Prior to joining Bone Therapeutics, Vandebroek served as director and CFO of Moteo Two Wheels and Bihr Europe, the motorcycle division of Alcopa Group, a Belgian family holding with an annual revenue of around 1.7 billion euros.
 
Bone Therapeutics is a cell therapy company addressing high unmet needs in orthopedics and bone diseases. Based in Gosselies, Belgium, the company has a diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation. The firm’s technology is based on a proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
 
The company’s primary clinical focus is ALLOB, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The company also has an autologous bone cell therapy product, PREOB, obtained from patient`s own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures. Bone Therapeutics‘ cell therapy products are protected by an IP estate covering nine patent families.